Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...

CLEVELAND, Ohio – First-line treatment with the proteasome inhibitor bortezomib (Velcade, Millennium Pharmaceuticals) plus dexamethasone and an alkylating agent (BDex+AA) improves survival in patients ...

Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for ...

AS plus ATTR-CA was associated with worse clinical outcomes than AS alone. Challenges of diagnosis stand in the way of timely treatment of ATTR-CA. Certain features associated with ATTR-CA and AS may ...

Physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine led a nationwide study to examine the role of carpal tunnel syndrome in predicting the risk of ...

Amyloidosis represents a heterogeneous group of disorders defined by the extracellular deposition of misfolded protein fibrils, which can cause severe impairment in multiple organs. In the context of ...

DEAR MAYO CLINIC: My dad was diagnosed with cardiac amyloidosis shortly after his 70th birthday. It’s difficult to pronounce let alone understand. What is cardiac amyloidosis? Am I at risk if it is ...

FRANKFORD (WPVI) -- Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being identified more and more. For Elsie McGruder, the first sign ...

Bayer is acquiring two investigational molecular imaging agents from Attralus for the diagnosis of cardiac amyloidosis.

Bayer to acquire AT-01 & AT-05, investigational molecular imaging agents for the diagnosis of cardiac amyloidosis from Attralus: Berlin, Germany Wednesday, January 14, 2026, 11:00 ...

Aortic valve narrowing (aortic stenosis) with concomitant cardiac amyloidosis is a severe heart disease of old age that is associated with a high risk of death. Until now, treatment has consisted of ...

Please provide your email address to receive an email when new articles are posted on . Vutrisiran improved all-cause mortality and recurrent CV independent of disease severity in cardiac amyloidosis.